Altamira Therapeutics completes patient enrollment in house dust mite allergy trial with Bentrio


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


HAMILTON, BERMUDA/ACCESSWIRE/March 15, 2022/ Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing treatments that address significant unmet medical needs, today announced the completion of patient enrollment in its Bentrio” trial for house dust mite allergic rhinitis. Domestic (“HDM”) will release initial trial results in the second quarter of 2022.

The trial, which enrolled a total of 37 patients with a history of perennial allergic rhinitis (“PAR”) caused by exposure to HDM, is designed to assess the effectiveness of Bentrio” in the treatment of PAR in a room environmental exposure (EEC), i.e. under controlled HDM exposure. Study participants were randomized in a three-period open-label crossover design to receive either Bentrio” as a single dose or double, i.e. no treatment before exposure to HDM for three hours. The primary endpoint will be the change in Total Nasal Symptom Score (TNSS) from baseline. The trial is being conducted at a single study site in Canada.

“House dust mite allergies are a very common problem, especially in more humid geographies, and can cause severe suffering and reduced quality of life,” commented Thomas Meyer, Founder, Chairman and CEO of Altamira. Therapeutics. “Following the positive results of our previous clinical investigation of Bentrio in grass pollen allergic rhinitis, we expect this new study to add to the growing body of evidence demonstrating the protective effects of Bentrio against multiple airborne allergens. in the air. In the meantime, we are continuing the commercial roll-out of Bentrio, helping to provide relief to the many allergy sufferers who were looking for an effective treatment without any drugs or preservative ingredients.”

About dust mite allergies

HDM allergens are the leading cause of respiratory allergies (i.e. allergic rhinitis and allergic asthma), with prevalence estimates of allergen sensitization ranging between 65 and 130 million people in the population worldwide, i.e. up to 50% in asthmatic patients.1 In the US population aged 6 and older, house dust mite allergens are the second most common source of sensitization just after plant-based allergens (20.3 and 27.1%, respectively).2 Unlike plant-based allergens, which tend to be seasonal (eg pollen/hay fever), HDMs can be present all year round. Symptoms of HDM allergies include sneezing, runny or stuffy nose, itching, coughing, difficulty breathing, chest tightness, or pain.

The references

1Calderon et al. (2015), Respiratory allergy caused by dust mites: what do we really know?, J Allergy Clin Immunol 136(1):38-48.

2Saleo et al. (2014), Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Survey (NHANES) 2005-2006. J Allergy Clin Immunol 134(2):350-9.

About Bentrio”

Bentrio” (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. When applied to the nose, Bentrio” forms a protective gel layer on the nose. nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with the cells; in addition, the composition serves to bind these particles and to promote their evacuation and to moisten the nasal mucosa. Together, this is designed to reduce the risk of viral upper respiratory infections and promote relief of allergy symptoms.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutic products that address significant unmet medical needs. The Company is currently active in three fields: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore” / SemaPhore” platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio”; commercial) or for the treatment of vertigo (AM-125; Phase 2) and the development of therapies for the intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3) The company was founded in 2003 and is based in Hamilton, Bermuda, with its principal operations in Basel, Switzerland The shares of Altamira Therapeutics Ltd.

Forward-looking statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact statements and may include statements that address future operational, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimates”, “predicts”, “plans”, “potential”, “outlook” or “continues”, or the negative form of these terms or any other comparable terminology. Forward-looking statements are based on the current expectations and beliefs of management and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include, but are not limited to, approval and timing of commercialization of AM-301, Altamira Therapeutics’ need and ability to secure substantial additional funding to further develop its product candidates, timing and conduct of studies clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and the financial condition of Altamira Therapeutics’ ‘Altamira Therapeutics, including the impact of any future acquisitions, dispositions, partnerships, licensing transactions or changes to Altamira Therapeutics’ capital structure, including future issuances of securities. These risks and uncertainties also include, but are not limited to, those described under “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the fiscal year ended December 31, 2020, and in other documents filed by Altamira Therapeutics with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to such risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics undertakes no obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. required.

Investor contacts:
Stephen Kilmer
646.274.3580
[email protected]

THE SOURCE: Altamira Therapeutic

See the source version on accesswire.com:
https://www.accesswire.com/693111/Altamira-Therapeutics-Completes-Patient-Enrollment-in-House-Dust-Mite-Allergy-Trial-with-Bentrio

Comments are closed.